We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ann
Shaw
Ann.Shaw@glasgow.ac.uk
Dr
Patricia
Roxburgh
patricia.roxburgh@glasgow.ac.uk
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
We are in an era of precision medicine where we aspire to make treatment decisions based on tumour molecular
characteristics. In current clinical practice, molecularly guided therapies (e.g. cetuximab in KRAS wild-type colorectal
cancer) have already improved patient outcomes.
Glasgow Experimental Cancer Medicine Centre (ECMC) has expertise in development of new molecularly targeted
drugs and supports conduct of early-phase clinical trials in the Clinical Research Unit (CRU) in Beatson West of
Scotland Cancer Centre (BWoSCC).
A central focus of the Glasgow Precision Oncology Laboratory (GPOL) at Wolfson Wohl Cancer Research Centre
(WWCRC), is to use the most advanced sequencing techniques to match the right treatment to the right patient.
In current practice the molecular information directing treatment is based on alterations in the diagnostic specimen
however evidence demonstrates that tumour at diagnosis is molecularly different than tumour following treatment.
Consequently, tumour molecular characterisation should be established ideally from an up-to-date biopsy.
We therefore need to establish mechanisms to take tumour biopsies and process them for molecular profiling in a
clinically useful timeframe (<6 weeks). We will also develop a process for interpretation of results and consideration of
their clinical relevance. Blood samples will also be taken to develop non-invasive methods of tumour profiling.
Additionally the molecular profiles generated will form a translational research repository to study biomarkers of
response and resistance.
The IMAGINE study is a feasibility study that will bring together Glasgow's expertise in development of new cancer
treatments and DNA sequencing. The study will recruit 200 patients over 5 years and allow an in depth analysis of
tumours from BWoSCC patients by GPOL. The initial aim is that a pathway is developed that allows molecular profile
data to be available quickly enough that it could influence the choice of the most appropriate experimental anti-cancer
treatment.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Not Specified;
You can take part if:
You may not be able to take part if:
None.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by GREATER GLASGOW AND CLYDE and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 45964
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
